A phase II/III Study of Paclitaxel/Carboplatin alone or Combined with either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzfx (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or C

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her2 Positive Endometrial Serous Carcinoma Or Carcinosarcoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. 1) Patients must have HER2-positive endometrial serous carcinoma or endometrial carcinosarcoma, have not received chemotherapy before and their cancer has not come back after treatment
    2. 2) Histologic confirmation of the original primary tumor
    3. 3) Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration

You may not be eligible for this study if the following are true:

    1. 1) Patients must not have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma
    2. 2) Patients must not have received prior radiation therapy for treatment of endometrial carcinoma
    3. 3) Patients must not have received prior hormonal therapy for treatment of endometrial carcinoma at least one week prior to registration



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.